Recent discussions on X about Johnson & Johnson (JNJ) have centered around the stock's performance, with shares recently hitting a new 52-week high and showing strong upward momentum. Many users have expressed optimism about the healthcare giant's trajectory, pointing to its consistent gains and potential to break further resistance levels in the near future. This buzz comes alongside reports of the stock surpassing analyst target prices, fueling conversations about its sustained strength.
Additionally, there has been notable chatter on X regarding insider activity and strategic developments within the company, with some highlighting a significant stock move by a top executive as a point of intrigue. While some see this as a potential signal of confidence, others are debating the implications amidst broader healthcare sector dynamics and external pressures like proposed taxes on foreign pharmaceutical products. The discussions reflect a complex mix of curiosity and speculation about what lies ahead for JNJ.
Note: This discussion summary was generated from an AI condensation of post data.
Johnson & Johnson Congressional Stock Trading
Members of Congress have traded $JNJ stock 20 times in the past 6 months. Of those trades, 9 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/17 and 1 sale worth up to $15,000 on 06/24.
- REPRESENTATIVE SCOTT FRANKLIN sold up to $50,000 on 06/16.
- REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 06/12.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/10, 03/04 and 0 sales.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $100,000 on 05/30, 03/31 and 1 sale worth up to $15,000 on 04/29.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 03/05, 02/24 and 1 sale worth up to $100,000 on 05/12.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 05/05.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 04/09, 03/07.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/01.
- REPRESENTATIVE GEORGE WHITESIDES sold up to $250,000 on 03/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Johnson & Johnson Insider Trading Activity
Johnson & Johnson insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOHN C REED (EVP, Innovative Medicine, R&D) sold 19,137 shares for an estimated $3,129,829
- JOSEPH J WOLK (Exec VP, CFO) sold 16,820 shares for an estimated $2,975,570
- ROBERT J DECKER (VP Corporate Controller) sold 6,999 shares for an estimated $1,160,994
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) sold 403 shares for an estimated $62,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Johnson & Johnson Hedge Fund Activity
We have seen 1,736 institutional investors add shares of Johnson & Johnson stock to their portfolio, and 2,186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GAMMA INVESTING LLC removed 7,166,000 shares (-99.3%) from their portfolio in Q2 2025, for an estimated $1,094,606,500
- BLACKROCK, INC. added 4,482,323 shares (+2.2%) to their portfolio in Q2 2025, for an estimated $684,674,838
- INVESCO LTD. removed 4,457,751 shares (-24.1%) from their portfolio in Q2 2025, for an estimated $680,921,465
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,319,402 shares (+20.3%) to their portfolio in Q2 2025, for an estimated $507,038,655
- CAPITAL INTERNATIONAL INVESTORS removed 3,101,458 shares (-83.8%) from their portfolio in Q2 2025, for an estimated $473,747,709
- VANGUARD GROUP INC added 3,085,180 shares (+1.3%) to their portfolio in Q2 2025, for an estimated $471,261,245
- ASSENAGON ASSET MANAGEMENT S.A. added 2,557,388 shares (+159.6%) to their portfolio in Q2 2025, for an estimated $390,641,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Johnson & Johnson Government Contracts
We have seen $39,755,137 of award payments to $JNJ over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- 4565676752!5.5MM TI CANN SCREW + ST - 65MM: $558,058
- 4566846440!TRILEAP MODULAR 1ST MTP SYSTEM: $506,953
- 8510979866!OTHER MEDICAL: $399,070
- 4565921178!2.4MM VA-LCP DISTAL: $363,348
- 4565956035!CSS+ SMALL SET: $290,401
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Johnson & Johnson Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 07/17/2025
- UBS issued a "Buy" rating on 07/17/2025
- Raymond James issued a "Outperform" rating on 04/16/2025
- Goldman Sachs issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for Johnson & Johnson, check out Quiver Quantitative's $JNJ forecast page.
Johnson & Johnson Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 9 analysts offer price targets for $JNJ in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $176.0 on 07/17/2025
- Terence Flynn from Morgan Stanley set a target price of $176.0 on 07/17/2025
- Vamil Divan from Guggenheim set a target price of $167.0 on 07/17/2025
- Shagun Singh from RBC Capital set a target price of $185.0 on 07/17/2025
- Tim Anderson from B of A Securities set a target price of $175.0 on 07/17/2025
- Danielle Antalffy from UBS set a target price of $190.0 on 07/17/2025
- David Risinger from Leerink Partners set a target price of $153.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
